M&A / Deals Incyte gobbles up Star’s Vega haematology unit in $2bn deal PharmaphorumIncyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Incyte has agreed to buy Star Therapeutics’ Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD. Hematology Read full story Post navigation Previous: Roche doubles down on BTK with $2.3bn Nurix dealNext: ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026